For research use only. Not for therapeutic Use.
Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.
Poloxime (100 μM) inhibits phosphopeptide binding to polo-box domain (PBD) of polo-like kinase 1 (Plk1)[2].
| Catalog Number | I002251 |
| CAS Number | 17302-61-3 |
| Synonyms | 5-methyl-4-nitroso-2-propan-2-ylphenol |
| Molecular Formula | C10H13NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H13NO2/c1-6(2)8-5-9(11-13)7(3)4-10(8)12/h4-6,12H,1-3H3 |
| InChIKey | YQVCMSSJMLGWAM-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C=C1N=O)C(C)C)O |
| Reference | [1]. Liu M, et al. Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors. Bioorg Med Chem Lett. 2015 Feb 1;25(3):431-4. [2]. Yin Z, et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem Biol. 2013 Feb 15;8(2):303-8. |
